Document:

ex10one.htm

 

 

 

 

 

 

 

September __, 2009

ValiRx Plc

24 Greville Street

London, ECIN 8SS

United Kingdom

Attn: James N. Thorniley, Chairman

Re:           Amendment No. 2 to Sale of Shares Agreement

Dear Mr. Thorniley,

The undersigned, Biofield Corp., a Delaware corporation (“Biofield” or the “Company”), hereby agrees with you (collectively, the “Parties”), as follows:

WHEREAS, the Parties entered into a Sale of Shares Agreement (the “Agreement”) for the sale and purchase of 623 shares (the “Shares”) of Valibio SA (“Valibio”) on December 11, 2008;

WHEREAS, certain payments were to be made by Biofield prior to the Completion Date (as defined in the Agreement) in connection with the purchase of the Shares which, to date, have not been made;

WHEREAS, On May 13, 2009, the Parties entered into a letter agreement amending the Agreement (the “Amendment”) whereby Biofield agreed to make payments towards the 660,000 Euro purchase price (the “Purchase Price”) prior to certain dates which, to date, have
not been made, and

WHEREAS, the Parties hereby wish to further amend the Agreement;

NOW THEREFORE IT IS AGREED:

	
  
	
1.
	
The payment date of the Purchase Price is hereby extended until December 31, 2009 (the “Termination Date”), or sooner as the parties may mutually agree in writing;

	
  
	
2.
	
As consideration for extending the payment date of the Purchase Price until December 31, 2009, or sooner as specified above, Mr. James MacKay shall, upon the execution of this Amendment No. 2 to the Agreement, transfer 1,500,000 shares
of preferred stock, par value $0.001 per share (the “Preferred Shares”), of Biofield Corp. to ValiRx, provided Mr. MacKay retains voting control of the Preferred Shares per the Voting Agreement executed as of the day hereof. It is the specific intent of the parties hereto that the Preferred Shares are to be held by ValiRx from the execution of this Amendment #2 through the amended Termination Date as security for the payment of the Purchase Price, in cash, by the Company, thereafter if the
Company has not paid the Purchase Price in full, then ValiRx shall be able to avail itself of the provisions of Section 5 below so that ValiRx may convert and attempt to sell such common shares in accordance with Section 5;

 

 

 

Page 1 of  4

 

175 Strafford Avenue – Suite One - Wayne, PA  19087 -  Ph. 215.972.1717 - Fax. 610.687.7737

 

  

  

  

 

 

 

 

 

	
  
	
3.
	
As disclosed in the Company’s Form 8-K filed January 23, 2008 with the Securities and Exchange Commission, ValiRx is aware that each share of the Preferred Shares entitles the holder thereto to two votes and the Board of Biofield has irrevocably resolved pursuant to Section 2.2 of the Certificate of Designation of Voting Preferred Stock, if the Purchase Price is not fully satisfied as of the amended Termination
Date specified herein, to convert the Preferred Shares into shares of common stock. (see attached Board Resolution dated x/x/x and incorporated herein);

	
  
	
4.
	
Subject to Section 5, the Preferred Shares shall be returned to Mr. MacKay upon the payment of the Purchase Price by Biofield to ValiRx;

	
  
	
5.
	
In the event the Purchase Price is not satisfied prior to the Termination Date, ValiRx may elect to either (i) convert the Preferred Shares into common stock and to apply the proceeds of any and all eventual sales in payment and satisfaction of the Purchase Price, or (ii) collect on the Purchase Price in full. If ValiRx chooses (i) above, it agrees that any such
sales of shares shall not exceed twenty percent (20%) of the total volume of the five (5) preceding trading days, on a weekly basis, and such sales shall be in an orderly manner so as not to depress the market price of the Company’s stock; and, further, if such converted shares are not enough to cover the unpaid balance of the Purchase price, additional shares shall be delivered to ValiRx to meet the obligation in full. Any shares remaining after the purchase Price has been paid, shall be returned.

	
  
	
6.
	
In the event Biofield raises funds in one or more private placements prior to December 31, 2009, Biofield shall satisfy the Purchase Price out of the use of proceeds of such raise by applying 10% of the proceeds below $500,000, plus 15% of the proceeds above $500,000 up to the Purchase Price.

 

[signature page follows]

 

Page 2  of  4

 

175 Strafford Avenue – Suite One - Wayne, PA  19087 -  Ph. 215.972.1717 - Fax. 610.687.7737

 

  

  

  

 

 

 

 

 

 

 

 

 

 

 

 

 

[signature page follows]

 

Page 3  of  4

 

175 Strafford Avenue – Suite One - Wayne, PA  19087 -  Ph. 215.972.1717 - Fax. 610.687.7737

 

  

  

  

 

 

 

 

[signature to letter agreement between Biofield and ValiRx 09/__/09)

BIOFIELD CORP.

By:

____________________________________                                                                          

David Bruce Hong, Chief Executive Officer

VALIRX PLC

By:

____________________________________                                                                          

James N. Thorniley, Chairman

JAMES R. MACKAY

 

____________________________________                                                                           

Individually

 

 

 

Page 4 of 4 

 

175 Strafford Avenue – Suite One - Wayne, PA  19087 -  Ph. 215.972.1717 - Fax. 610.687.7737ex10two.htm

 

 

 

 

VOTING AGREEMENT

VOTING AGREEMENT, dated as of September __, 2009, between James MacKay (“MacKay”), individually, and ValiRx Plc. (“ValiRx”),
(each, a "Shareholder" and together, the "Shareholders").

      WHEREAS:

A. As of the date hereof, MacKay owns, beneficially and/or of record, 12,300,000 shares of preferred stock, $0.001 par value per share (the "Preferred Stock"), of Biofield Corp., a Delaware corporation (the "Company");

B. The Shareholders have entered into a Letter Agreement dated September __, 2009 (the “Letter Agreement”), whereby MacKay has pledged as security One Million Five Hundred Thousand (1,500,000) shares of the Preferred Stock to ValiRx (the “Pledged
Shares”);

C. Each Shareholder desires to enter into this Agreement with respect to the voting of the Pledged Shares now held, beneficially and/or of record, by ValiRx on the terms and conditions set forth herein.

     NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:

1. Agreement to Vote. (a) In recognition of the Shareholders' common goals and objectives as shareholders of the Company and to ensure the orderly management and operation of the Company, each Shareholder hereby agrees that during the time this Agreement is in effect, at any meeting of
the shareholders of the Company, however called, and in any action by consent of the shareholders of the Company, MacKay shall:

(a) appear at the meeting or otherwise cause the Pledged Shares to be counted as present thereat for purposes of establishing a quorum;

(b) vote, or execute consents in respect of the Pledged Shares, or cause the Pledged Shares to be voted, or consents to be executed in respect thereof, in a manner that he believes is in the best interest of the Company and its shareholders;

2. Irrevocable Proxy.  ValiRx hereby irrevocably constitutes and appoints MacKay as its attorney and proxy in accordance with Delaware Corporate Law, with full power of substitution and re-substitution, to cause the Pledged Shares to be counted as present at any Company Stockholders Meetings to vote his, her or its shares at
any Company Stockholders' Meeting, however called, and execute consents in respect of his, her or its shares as and to the extent provided in Section 1. THIS PROXY AND POWER OF ATTORNEY UPON ITS EFFECTIVENESS WILL BE IRREVOCABLE AND COUPLED WITH AN INTEREST. ValiRx hereby revokes all other proxies and powers of attorney with respect to his, her or its shares that he, she or it may have heretofore appointed or granted, and no subsequent proxy or power of attorney shall be granted, in each case to the extent such
prior or subsequent proxies or powers of attorney would prevent ValiRx from complying with such stockholder's obligations under this Agreement.

 

 

 

 

 

 

 

 

                      3.  Legend. Any stock certificates representing the Pledged Shares owned by a Shareholder shall bear an appropriate legend relating to this Agreement.

                      4. Representations and Warranties of the MacKay. MacKay hereby represents and warrants to Stockholder as follows:

                                   (a) Due Authorization; Enforceability. MacKay has full power and authority to execute and deliver this Agreement. The execution
and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly and validly authorized by all necessary action on the part of MacKay, and no other proceedings on the part of MacKay are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by MacKay and constitutes a valid and binding agreement by MacKay, enforceable against such Stockholder in accordance with its terms,
subject to applicable bankruptcy, insolvency, moratorium or other similar laws relating to creditors' rights and to general principles of equity.

                                   (b) No Conflicts. No authorization, consent or approval of, or filing with, any court or any public body or authority is necessary
for the consummation by the Stockholder of the transactions contemplated by this Agreement. The execution, delivery and performance of this Agreement by the Stockholder will not constitute a breach, violation or default (or any event which, with notice or lapse of time or both, would constitute a default) under, or result in the termination of, or accelerate the performance required by, or result in a right of termination or acceleration under, or result in the creation of any lien or encumbrance upon any of
the properties or assets of such Stockholder under, any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument to which such Stockholder is a party or by which his, her or its properties or assets are bound, other than breaches, violations, defaults, terminations, accelerations or creation of liens and encumbrances which, in the aggregate, would not materially impair the ability of such Stockholder to perform his, her or its obligations hereunder.

 

                      4. Representations and Warranties of the ValiRx. ValiRx hereby represents and warrants to Stockholder as follows:

 

                                   (a) Organization; Due Authorization; Enforceability. Stockholder is corporation duly organized, validly existing and in good standing under the laws of England and Wales..

 

                                   (b) No Encumbrances.  Stockholder has good, valid and marketable title to the Pledged Shares, free and clear of all
security interests, liens, claims, pledges, options, rights of first refusal, agreements, limitations on Stockholder's voting.

 

                                   (c) Due Authorization; Enforceability. ValiRx has full power and authority to execute and deliver this Agreement. The execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby have been duly and validly authorized by all necessary action on the part of ValiRx, and no other proceedings on the part of ValiRx are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by ValiRx and constitutes a valid and binding agreement by ValiRx, enforceable against such Stockholder in accordance with its terms, subject to applicable bankruptcy, insolvency, moratorium
or other similar laws relating to creditors' rights and to general principles of equity.

 

 

 

 

 

- 2 -

 

 

                                  (d) No Conflicts. No authorization, consent or approval of, or filing with, any court or any public body or authority is necessary for
the consummation by the Stockholder of the transactions contemplated by this Agreement. The execution, delivery and performance of this Agreement by the Stockholder will not constitute a breach, violation or default (or any event which, with notice or lapse of time or both, would constitute a default) under, or result in the termination of, or accelerate the performance required by, or result in a right of termination or acceleration under, or result in the creation of any lien or encumbrance upon any of the
properties or assets of such Stockholder under, any note, bond, mortgage, indenture, deed of trust, license, lease, agreement or other instrument to which such Stockholder is a party or by which his, her or its properties or assets are bound, other than breaches, violations, defaults, terminations, accelerations or creation of liens and encumbrances which, in the aggregate, would not materially impair the ability of such Stockholder to perform his, her or its obligations hereunder.

                                   (e) Brokers. No broker, finder or investment banker is entitled to any brokerage, finder's or other fee or commission in connection
with the transactions contemplated hereby based upon arrangements made by or on behalf of the Stockholder.

5. Stockholder Covenants. ValiRx hereby covenants and agrees as follows:

                                   (a) ValiRx hereby agrees, while this Agreement is in effect, and except as contemplated hereby, not to sell, transfer, pledge, encumber,
assign or otherwise dispose of, or enter into any contract, option or other arrangement or understanding with respect to the sale, transfer, pledge, encumbrance, assignment or other disposition of (all of the foregoing, "Sell," "Sold" or "Sale," as the case may be), any of the Pledged Shares.

                                   (b) ValiRx hereby agrees, while this Agreement is in effect, to notify MacKay promptly of the number of new shares of capital stock
or stock options of the Company acquired by such Stockholder, if any, after the date of this Agreement.

6. No Inconsistent Agreements. Each Shareholder hereby covenants and agrees that, except as contemplated by this Agreement, so long as this Agreement remains in effect, he or she (a) shall not enter into any other voting agreement with respect to his or her Shares and (b) shall not grant
a proxy or power of attorney with respect to his or her Shares, in each such case, which is inconsistent with its obligations pursuant to this Agreement.

7. Shareholder Capacity. Nothing in this Agreement shall limit or restrict either Shareholder in acting in his or her capacity as a director of the Company and exercising his or her fiduciary duties and responsibilities relating thereto, it being understood that this Agreement shall apply
to each Shareholder solely in his or her capacity as a shareholder of the Company and shall not apply to each Shareholders' actions, judgments or decisions as a director of the Company.

8. Amendments and Waivers. No amendment or waiver of any provision of this Agreement shall be valid unless the same shall be in writing and signed by both Shareholders. No waiver by either party of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional
or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.

 

 

 

 

- 3 -

 

 

9. Term of the Agreement. This Agreement shall expire on the earlier of: (i) January 1, 2010 or (ii) the payment in full of the Purchase Price..

10. Miscellaneous. (a) This Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Pennsylvania without regard to the conflicts of law principles thereof.

(a) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supercedes all prior agreements and understandings, both written and oral, between the parties hereto with respect to the subject matter hereof. If any of the provisions of this Agreement are for any reason declared
by the final judgment of a court of competent jurisdiction to be unenforceable or ineffective, those provisions shall be deemed severable from the other provisions of this Agreement and the remainder of this Agreement shall remain in full force and effect.

(b) This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto (individually and as attorney-in-fact, trustee, executor, custodian or otherwise, if applicable) and their respective successors, assigns, heirs, legal representatives and personal representatives. If a Shareholder effectuates
any transfer to which the preceding sentence applies, he or she shall, as a condition to such transfer, first obtain an agreement in writing from such transferee to be bound by all of the terms and provisions of this Agreement with the same force and effect as if such transferee were (and such transferee shall be considered) a "Shareholder" for all purposes of this Agreement as of the date hereof. Notwithstanding anything to the contrary contained herein, a transferee acquiring any Shares from a Shareholder in
a public offering or via a public sale shall not be bound by the terms and conditions of this Agreement.

(c) This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[signature page follows]

 

 

 

  

- 4 -

  

IN WITNESS WHEREOF, this Agreement has been executed and delivered by the parties hereto as of the day and year first above written.

	  	  	 
	  	
VALIRX PLC
	 
	  	  	 
	  	
/s/
	 
	  	
By:  James N. Thorniley
	 
	  	
        Chairman
	 
	  	  	 
	  	  	 
	  	
JAMES R. MACKAY
	 
	  	  	 
	  	
Individually
	 

 

 

 

- 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]